Dealing with anxiety is challenging. Whether it’s induced by stress, work, hormonal imbalance, or other reasons, anxiety can ...

Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising results, with improved response rates and potential ...

MG’s next electric car for Australia has been approved for sale, with three battery sizes – and a different name to what’s ...

Cardiff Oncology CRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead ...

Cardiff Oncology's promising Phase 2 trial data for Onvansertib in colorectal cancer may lead to accelerated FDA approval, ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate ...

Social media warnings, food insecurity, unsafe hospitals, "forever chemicals," underinsured put off care, AI, vaccines, and ...

Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated ...

This highly potent oil packs a punch with 2500 mg in each 30 mL bottle — a whopping 83 mg of CBD per serving ... CBD oil with the added peace of mind that it is derived from hemp and contains less ...

The combination of BRUKINSA and our investigational BCL2 inhibitor, sonrotoclax, demonstrated significant potential as a first-line therapy in CLL, with a 99% overall response rate ... with BRUKINSA ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from ...